Desmopressin for Bleeding Related to Low Body Temperature

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study, with a prospective randomised controlled design, whether the subcutaneous administration of the haemostatic drug desmopressin, may improve the impairment of primary haemostasis due to mildly decreased temperature.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures

NCT02368730

Platelet Dysfunction

COMPLETED

Normothermia in Patients With Acute Cerebral Damage

NCT00491192

Traumatic Brain Injury Subarachnoid Hemorrhage

UNKNOWN PHASE4

Use of Nitroglycerine to Improve Signs of Poor Peripheral Perfusion in Patients With Traumatic Hemorrhagic Shock

NCT03235921

Hemorrhagic Shock

UNKNOWN PHASE2

Dexmedetomidine Pharmacokinetics in Neonates During Therapeutic Hypothermia

NCT02529202

Hypoxic-ischemic Encephalopathy

COMPLETED EARLY_PHASE1

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

NCT00961532

Intracerebral Hemorrhage

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypothermia Induced Impairment of Primary Haemostasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

single desmopressin subcutaneous injection, 1.5mcg

Intervention Type DRUG

desmopressin

single desmopressin subcutaneous injection, 3mcg

Intervention Type DRUG

desmopressin

single desmopressin subcutaneous injection, 15mcg

Intervention Type DRUG

placebo

saline subcutaneous

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Healthy volunteers

Exclusion Criteria

1. Any known platelet or coagulation disorder.
2. Pregnant or lactating women.
3. Known chronic liver or renal disease.
4. Coronary artery, carotid artery or peripheral artery disease
5. Recent history of taking antiplatelet drugs, anticoagulants or herbal preparations.
6. Smoker or alcohol user
7. Mentally incapable of providing informed consent
8. Students or junior staff members who had direct working relationship with the PI

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes